Literature DB >> 6706938

Amino acid sequence of human plasma apolipoprotein C-II from normal and hyperlipoproteinemic subjects.

A V Hospattankar, T Fairwell, R Ronan, H B Brewer.   

Abstract

The complete amino acid sequence of human plasma apolipoprotein C-II isolated from normal individuals and a subject with type V hyperlipoproteinemia has been determined. Apo-C-II contains 79 amino acids with the following amino acid composition: Asp4, Asn1, Thr9, Ser9, Glu7, Gln7, Pro4, Gly2, Ala6, Val4, Met2, Ile1, Leu8, Tyr5, Phe2, Lys6, Arg1, Trp1. Cleavage of apo-C-II by cyanogen bromide produced three peptides designated as CB-1 (9 residues), CB-2 (51 residues), and CB-3 (19 residues). Two peptides, CT-1 (50 residues) and CT-2 (29 residues), which overlapped the cyanogen bromide peptides, were obtained by tryptic digestion of citraconylated apo-C-II at the single arginine residue. The amino acid sequence of apo-C-II was obtained by the automated phenyl isothiocyanate degradation of intact apo-C-II and the peptides produced by cleavage of apo-C-II by cyanogen bromide and trypsin. Phenylthiohydantoins were identified by high performance liquid chromatography and chemical ionization-mass spectrometry. The amino acid sequence of apo-C-II from the normal subject was identical with the apo-C-II isolated from the hyperlipoproteinemic subject.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6706938

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

Review 1.  Omega-3 fatty acids, lipids, and apoE lipidation in Alzheimer's disease: a rationale for multi-nutrient dementia prevention.

Authors:  Marcus O W Grimm; Daniel M Michaelson; Tobias Hartmann
Journal:  J Lipid Res       Date:  2017-05-20       Impact factor: 5.922

2.  Purification, cloning and nucleotide sequence determination of cynomolgus monkey apolipoprotein C-II: comparison to the human sequence.

Authors:  B E Whitted; C K Castle; H G Polites; G W Melchior; K R Marotti
Journal:  Mol Cell Biochem       Date:  1989-10-05       Impact factor: 3.396

3.  A nonsense mutation in the apolipoprotein C-IIPadova gene in a patient with apolipoprotein C-II deficiency.

Authors:  S S Fojo; P Lohse; C Parrott; G Baggio; C Gabelli; F Thomas; J Hoffman; H B Brewer
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

4.  Longitudinal analysis of maternal plasma apolipoproteins in pregnancy: a targeted proteomics approach.

Authors:  Shannon K Flood-Nichols; Deborah Tinnemore; Mark A Wingerd; Ali I Abu-Alya; Peter G Napolitano; Jonathan D Stallings; Danielle L Ippolito
Journal:  Mol Cell Proteomics       Date:  2012-10-10       Impact factor: 5.911

5.  Biophysical properties of apolipoprotein E4 variants: implications in molecular mechanisms of correction of hypertriglyceridemia.

Authors:  Irina N Gorshkova; Kyriakos E Kypreos; Donald L Gantz; Vassilis I Zannis; David Atkinson
Journal:  Biochemistry       Date:  2008-11-25       Impact factor: 3.162

6.  Human apolipoproteins AI, AII, CII and CIII. cDNA sequences and mRNA abundance.

Authors:  C R Sharpe; A Sidoli; C S Shelley; M A Lucero; C C Shoulders; F E Baralle
Journal:  Nucleic Acids Res       Date:  1984-05-11       Impact factor: 16.971

7.  Apo C-II deficiency type Bari.

Authors:  A Capurso; F Resta; F Turturro; A M Colacicco; C Crecchio; G Pepe
Journal:  Eur J Epidemiol       Date:  1992-05       Impact factor: 8.082

8.  Apolipoprotein CIISt. Michael. Familial apolipoprotein CII deficiency associated with premature vascular disease.

Authors:  P W Connelly; G F Maguire; J A Little
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

9.  Human plasma apolipoprotein C-II: total solid-phase synthesis and chemical and biological characterization.

Authors:  T Fairwell; A V Hospattankar; H B Brewer; S A Khan
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

10.  Electrophoretic screening for human apolipoprotein C-II variants: repeated identification of apolipoprotein C-II(K19T).

Authors:  H Wiebusch; J R Nofer; A von Eckardstein; H Funke; U Wahrburg; H Martin; E Köhler; G Assmann
Journal:  J Mol Med (Berl)       Date:  1995-07       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.